Answers are grounded in this paper and cite their sources.
Clinical imaging with PSMA PET/CT significantly alters treatment for high-risk prostate cancer, suggesting its critical role.
PSMA PET/CT with ¹⁸F-flotufolastat led to clinical upstaging in nearly one-third of men with high-risk prostate cancer and negative conventional imaging, resulting in significant treatment change in most patients. These findings support the integration of PSMA-targeted imaging into initial staging pathways for men with high-risk prostate cancer.
No takes yet. Share an insight, caveat, or question.
Taylor et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: